G6PD
Overview
G6PD encodes glucose-6-phosphate dehydrogenase, the rate-limiting enzyme of the pentose phosphate pathway (PPP). The PPP generates NADPH for antioxidant defense and ribose-5-phosphate for nucleotide biosynthesis, making G6PD central to the metabolic reprogramming observed in many cancers. In ccRCC, G6PD is highlighted as part of the Warburg-like metabolic shift in aggressive tumors.
Alterations observed in the corpus
- Highlighted as a downstream pathway and SCNA feature in focal-deletion analyses in clear-cell renal cell carcinoma (ccRCC); pentose phosphate pathway activity (including G6PD) proposed as a candidate therapeutic-vulnerability indicator given the Warburg-like metabolic shift in aggressive tumors PMID:23792563
Cancer types (linked)
- CCRCC — G6PD-mediated pentose phosphate pathway activity is part of the metabolic reprogramming landscape identified by comprehensive multi-omic profiling; proposed as both prognostic and therapeutic target PMID:23792563
Co-occurrence and mutual exclusivity
- Co-listed with FASN, CTNNB1, TGFBR2, and other metabolic and pathway genes in ccRCC analyses PMID:23792563
Therapeutic relevance
- Pentose phosphate pathway including G6PD proposed as a candidate therapeutic-vulnerability indicator in aggressive ccRCC alongside AMPK and ACC PMID:23792563
Open questions
- Specific frequency of G6PD copy-number or expression alterations is not individually detailed in the ccRCC TCGA cohort PMID:23792563
Sources
This page was processed by crosslinker on 2026-05-09.